Aldeyra needs more Tranquility
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
